Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy

Abnormal structural and molecular changes in malignant tissues were thoroughly investigated and utilized to target tumor cells, hence rescuing normal healthy tissues and lowering the unwanted side effects as non-specific cytotoxicity. Various ligands for cancer cell specific markers have been uncove...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Layla Al-mansoori, Philip Elsinga, Sayed K. Goda
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Cancer specific receptors Cancer specific antibody Tumor specific peptide carriers Cancer overexpressed proteins Targeted cancer strategies mRNA vaccine for cancer therapy Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/02c94a827e154a48a2cc15bc82004766
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:02c94a827e154a48a2cc15bc82004766
record_format	dspace
spelling	oai:doaj.org-article:02c94a827e154a48a2cc15bc820047662021-11-14T04:28:57ZBio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy0753-332210.1016/j.biopha.2021.112260https://doaj.org/article/02c94a827e154a48a2cc15bc820047662021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S0753332221010441https://doaj.org/toc/0753-3322Abnormal structural and molecular changes in malignant tissues were thoroughly investigated and utilized to target tumor cells, hence rescuing normal healthy tissues and lowering the unwanted side effects as non-specific cytotoxicity. Various ligands for cancer cell specific markers have been uncovered and inspected for directional delivery of the anti-cancer drug to the tumor site, in addition to diagnostic applications. Over the past few decades research related to the ligand targeted therapy (LTT) increased tremendously aiming to treat various pathologies, mainly cancers with well exclusive markers. Malignant tumors are known to induce elevated levels of a variety of proteins and peptides known as cancer “markers” as certain antigens (e.g., Prostate specific membrane antigen “PSMA”, carcinoembryonic antigen “CEA”), receptors (folate receptor, somatostatin receptor), integrins (Integrin αvβ3) and cluster of differentiation molecules (CD13). The choice of an appropriate marker to be targeted and the design of effective ligand-drug conjugate all has to be carefully selected to generate the required therapeutic effect. Moreover, since some tumors express aberrantly high levels of more than one marker, some approaches investigated targeting cancer cells with more than one ligand (dual or multi targeting). We aim in this review to report an update on the cancer-specific receptors and the vehicles to deliver cytotoxic drugs, including recent advancements on nano delivery systems and their implementation in targeted cancer therapy. We will discuss the advantages and limitations facing this approach and possible solutions to mitigate these obstacles. To achieve the said aim a literature search in electronic data bases (PubMed and others) using keywords “Cancer specific receptors, cancer specific antibody, tumor specific peptide carriers, cancer overexpressed proteins, gold nanotechnology and gold nanoparticles in cancer treatment” was carried out.Layla Al-mansooriPhilip ElsingaSayed K. GodaElsevierarticleCancer specific receptorsCancer specific antibodyTumor specific peptide carriersCancer overexpressed proteinsTargeted cancer strategiesmRNA vaccine for cancer therapyTherapeutics. PharmacologyRM1-950ENBiomedicine & Pharmacotherapy, Vol 144, Iss , Pp 112260- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cancer specific receptors Cancer specific antibody Tumor specific peptide carriers Cancer overexpressed proteins Targeted cancer strategies mRNA vaccine for cancer therapy Therapeutics. Pharmacology RM1-950
spellingShingle	Cancer specific receptors Cancer specific antibody Tumor specific peptide carriers Cancer overexpressed proteins Targeted cancer strategies mRNA vaccine for cancer therapy Therapeutics. Pharmacology RM1-950 Layla Al-mansoori Philip Elsinga Sayed K. Goda Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy
description	Abnormal structural and molecular changes in malignant tissues were thoroughly investigated and utilized to target tumor cells, hence rescuing normal healthy tissues and lowering the unwanted side effects as non-specific cytotoxicity. Various ligands for cancer cell specific markers have been uncovered and inspected for directional delivery of the anti-cancer drug to the tumor site, in addition to diagnostic applications. Over the past few decades research related to the ligand targeted therapy (LTT) increased tremendously aiming to treat various pathologies, mainly cancers with well exclusive markers. Malignant tumors are known to induce elevated levels of a variety of proteins and peptides known as cancer “markers” as certain antigens (e.g., Prostate specific membrane antigen “PSMA”, carcinoembryonic antigen “CEA”), receptors (folate receptor, somatostatin receptor), integrins (Integrin αvβ3) and cluster of differentiation molecules (CD13). The choice of an appropriate marker to be targeted and the design of effective ligand-drug conjugate all has to be carefully selected to generate the required therapeutic effect. Moreover, since some tumors express aberrantly high levels of more than one marker, some approaches investigated targeting cancer cells with more than one ligand (dual or multi targeting). We aim in this review to report an update on the cancer-specific receptors and the vehicles to deliver cytotoxic drugs, including recent advancements on nano delivery systems and their implementation in targeted cancer therapy. We will discuss the advantages and limitations facing this approach and possible solutions to mitigate these obstacles. To achieve the said aim a literature search in electronic data bases (PubMed and others) using keywords “Cancer specific receptors, cancer specific antibody, tumor specific peptide carriers, cancer overexpressed proteins, gold nanotechnology and gold nanoparticles in cancer treatment” was carried out.
format	article
author	Layla Al-mansoori Philip Elsinga Sayed K. Goda
author_facet	Layla Al-mansoori Philip Elsinga Sayed K. Goda
author_sort	Layla Al-mansoori
title	Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy
title_short	Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy
title_full	Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy
title_fullStr	Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy
title_full_unstemmed	Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy
title_sort	bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/02c94a827e154a48a2cc15bc82004766
work_keys_str_mv	AT laylaalmansoori biovehiclesofcytotoxicdrugsfordeliverytotumorspecifictargetsforcancerprecisiontherapy AT philipelsinga biovehiclesofcytotoxicdrugsfordeliverytotumorspecifictargetsforcancerprecisiontherapy AT sayedkgoda biovehiclesofcytotoxicdrugsfordeliverytotumorspecifictargetsforcancerprecisiontherapy
_version_	1718429997170950144

Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy

Ejemplares similares